2011-10-03T12:53:45-05:00 2010-12-31 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2010-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Michael W Marine 2028428610 2011-10-03 1 Nicole M Simon CPA 7038930300 2011-10-03 2010 2016-03-07 17:11:31Z Michael W Marine 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 21101687 0 X www.sabin.org X 1994 MD An organization of scientists, researchers and advocates for a world free of needless suffering. 12 11 54 0 0 0 17123901 21076480 5000 0 74383 25207 0 0 17203284 21101687 10013058 7920650 0 0 3461279 3791300 297631 720011 775318 6400803 4473509 20172771 16905470 -2969487 4196217 22552634 26815225 3554288 3620662 18998346 23194563 X Sabin's mission is to reduce needless human suffering from vaccine preventable and neglected tropical diseases through innovative vaccine research and development; and to advocate for improved access to vaccines and essential medicines for citizens around the globe. 0 0 6256984 5096824 Vaccine Development Program - In collaboration with the partners of our Product Development Partnership (PDP), Sabin Vaccine Development has made significant progress in 2010, which was our 10-year anniversary of the program.Human Hookworm Vaccine Initiative - In 2010, Sabin's Vaccine Development Program completed preparation of a new Investigative New Drug (IND) submission for the Na-GST-1 hookworm vaccine, including a successful pre-IND meeting with the U.S. Food and Drug Administration (FDA) and completion of a preclinical animal toxicology study. The IND application for this candidate vaccine will be made in January 2011 and Phase I clinical trials initiated later in the year. The group also completed production of cell banks for Na-APR-1, another hookworm antigen, the first step in manufacture of this candidate. Schistosomiasis Vaccine Initiative- The Sabin Vaccine Development group has also has identified a promising intestinal schistosomiasis vaccine antigen, Sm-TSP-2, and has completed production of cell banks for that antigen, while continuing technology transfer of manufacturing processes to Instituto Butantan in Brazil. Malaria Vaccine Project - In 2010, Sabin's Vaccine Development group also continued work in a partnership that is developing a potential malaria vaccine, Anopheline alanyl aminopeptidase-1 (AnAPN1). As featured in Time Magazine, this vaccine would be unique in that it is based on the concept of blocking transmission of the parasite so that a mosquito that feeds off the blood of someone who has been immunized can no longer pass on the organism to another person. Through our PDP model, Sabin Vaccine Development has optimized expression of AnAPN1 in yeast and bacterial vectors. After identifying an optimal expression system, researchers are now refining the manufacturing process to produce the AnAPN1 antigen, as well as developing release and stability tests necessary to assess its identity, purity, potency and stability. 4310698 2392840 Global Network for Neglected Tropical Diseases Program - The Global Network for Neglected Tropical Diseases (Global Network) is dedicated to raising the awareness, political will, and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs) - a group of disabling, disfiguring, and deadly diseases affecting more than 1.4 billion people worldwide living on less than $1.25 a day. Through strong collaboration with the World Health Organization (WHO), national health ministries, international organizations, pharmaceutical companies, donors and affected communities, the Global Network strives to impact control and elimination of these diseases of poverty. We support WHO's efforts to develop integrated NTD national plans of action and develop coordinated advocacy and resource mobilization activities. The Global Network supports NTD control through mass drug administration (MDA) that has been integrated into existing delivery systems, including immunization campaigns, Child Health Days, school health programs, routine health delivery services, and Vitamin A campaigns. We also work to create regional funding mechanisms that support these NTD control and elimination programs. Advocacy efforts helped underline the importance of the increased funding commitments by the U.S. and UK governments and increased awareness of NTDs through media placements, speeches, and educational visits. 3967816 430986 Vaccine Advocacy and Education Programs - The Sabin Vaccine Institute's Vaccine Advocacy and Education program works together with leading health experts and organizations to promote awareness and increased utilization of both traditional and new, underutilized vaccines. In 2010 it held three large symposia (South Africa, Brazil & Peru) which brought together over 700 people to discuss relevant research and updates that will inform public health agendas related to rotavirus, pertussis, rubella, human papilloma-virus (HPV) and pneumococcal disease; as well as to reflect on the lessons learned from the successful campaign to eradicate smallpox.The Sustainable Immunization Financing (SIF) program is operating in twelve African, and three Asian pilot countries on advocacy-driven initiatives for sustainable immunization financing. SIF invites key stakeholders, parliamentarians, and members of ministries of health and finance to come up with innovative solutions for the continued and fiscal support of a program vital to public health. Outputs from such meetings have ranged from declarations and ideas for tax revenue funding, to conceiving financing mechanisms, all in support of this initiative.The Coalition against Typhoid (CaT) Secretariat was founded in September 2010. The Secretariat's purpose is to facilitate progress towards the CaT goal of expediting and sustaining evidence-informed decisions regarding the use of typhoid vaccination to prevent childhood enteric fever. Participation in the coalition is open to any institution interested in contributing to the prevention and control of typhoid fever and includes 18 organizations, among them the World Health Organization (WHO), UNICEF, Oxford University and the Welcome Trust Sanger Institute. 14535498 1 1 0 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 25 0 54 1 0 0 0 0 0 0 0 0 0 0 X 12 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY X The Organization 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Louis Cooper 1.00 X 0 0 0 Allan Goldstein 1.00 X 0 0 0 Lance Gordon 1.00 X 0 0 0 Alan Greenberg 1.00 X 0 0 0 Axel Hoos 1.00 X 0 0 0 Mort Hyman 20.00 X X 0 0 0 Kevin Reilly 1.00 X 0 0 0 Phillip Russell 5.00 X 41232 0 0 Jim Scott 1.00 X 0 0 0 Peter Thoren 1.00 X 0 0 0 Mike Whitham 1.00 X X 0 0 0 Seble Frehywot 1.00 X 0 0 0 Ciro de Quadros 40.00 X 323692 0 1450 Peter Hotez 20.00 X 35000 0 0 Brian Davis 40.00 X 219967 0 23086 Michael Marine 40.00 X 233057 0 9665 Stephanie Hedean 40.00 X 185101 0 10771 David Diemert 40.00 X 170663 0 13503 Mike McQuestion 40.00 X 150715 0 20913 Ami Shah Brown 40.00 X 127111 0 15253 Neeraj Mistry 40.00 X 104084 0 560 Kelly Funk 40.00 X 193177 0 0 Kari Stoever 40.00 X 385000 0 0 2168799 0 95201 11 1 1 0 Changing our World 220 East 42nd St 7th Flr New York NY 10017 Resource development strategy & support 720011 GMMB 101 Wisconsin Avenue NW Washington DC 20007 Pneumococcal vaccine advocacy 408501 APCO Worldwide 700 12th Street NW Suite 800 Washington DC 20005 Communication services 165154 Home Front Communications 1121 14th Street Washington DC 20005 Communication services 132661 Fraunhofer USA Inc PO Box 673308 Detroit MI 48267 Vaccine manufacture 124500 5 21076480 21076480 25207 25207 21101687 0 0 25207 4933944 4933944 2986706 2986706 887148 732914 147454 6780 2400556 1987373 395614 17569 51421 40257 10355 809 258739 202566 52104 4069 193436 160288 31367 1781 124013 100294 23719 13380 10821 2559 720011 720011 858739 591694 266629 416 612002 609674 2328 295541 254232 39451 1858 183612 131665 51947 522446 62674 459772 711625 667373 24620 19632 935277 928715 5696 866 2457 1270 1187 15661 15661 56592 16006 40586 Recruiting 66876 51524 14901 451 Dues and subscriptions 40877 38293 2584 Miscellaneous 22901 18306 4535 60 Bank fees 7284 6341 943 Books and publications 4226 2568 642 1016 16905470 14535498 1594654 775318 18623652 24339796 758437 577493 2549401 1712316 97035 97680 222806 183739 54728 39067 469381 48873 22552634 26815225 2889732 2937947 472376 472376 192180 210339 3554288 3620662 X 2321029 1806523 16677317 21388040 18998346 23194563 22552634 26815225 4196217 X X 0 1 1 X 0 X 11442210 15829944 25512242 17123901 21076480 90984777 11442210 15829944 25512242 17123901 21076480 90984777 70859109 20125668 206125 390893 241594 92623 25207 956442 91941219 892383 0.21890 0.27810 X The Organization has maintained a continuous and bona fide program for solicitation of funds from the general public, community, government units, and other charities. The public support percentage for both 2010 and 2009 was approximately 22% and 28%, respectively, since some donations for use in the Organization's charitable programs from several contributors were larger than anticipated. As contained in the program descriptions in Part III of Form 990, the Organization's program services directly benefit the general public on a continuing basis. While certain large Foundation grants may continue in the near term, this support is crucial to the Organization's exempt purpose of promoting and contributing to the control of infectious and neglected tropical diseases. The Organization expects to continue to solicit qualifying public support to assist in carrying out these programs. Finally, the Organization's governing body represents the broad interest of the public, with no one individual or related group of individuals having undue control or influence over the Organization's funding or affairs. These Board members bring important skill sets and qualifications that help the Organization plan and achieve its strategic objectives. Accordingly, the "facts and circumstances" substantiate that the Organization continues to operate as a public charity. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 222806 183739 39067 0 39067 Obligation under capital lease 12997 Deferred rent 197342 210339 21101687 16905470 4196217 0 4196217 21370503 268816 268816 21101687 0 21101687 17174286 268816 268816 16905470 0 16905470 Description of Uncertain Tax Positions Under FIN 48: Part X: The Organization has no significant uncertain tax positions during the year ended December 31, 2010. 1 Middle East and North Africa 0 0 Grants to recipients located in region. 109247 Europe (Including Iceland & Greenland) 0 0 Grants to recipients located in region. 952940 South America 0 0 Grants to recipients located in region. 1089469 East Asia and the Pacific 0 0 Grants to recipients located in region. 835049 0 0 0 2986705 0 2986705 South America Vaccine Development 164243 EFT Europe (Including Iceland & Greenland) NTD Control 419535 EFT South America NTD Control 100057 EFT South America Vaccine Development 825168 EFT Europe (Including Iceland & Greenland) NTD Control 156777 EFT Europe (Including Iceland & Greenland) NTD Control 92213 EFT East Asia and the Pacific Vaccine Development 50000 EFT East Asia and the Pacific Vaccine Development 148086 EFT Middle East and North Africa NTD control 109247 EFT East Asia and the Pacific Vaccine Development 175453 EFT East Asia and the Pacific NTD Control 205000 EFT East Asia and the Pacific NTD Control 256510 EFT East Asia and the Pacific NTD Control 284415 EFT 13 0 0 0 0 0 0 Procedure for Monitoring Grants Outside the U.S.: Schedule F, Part I, Line 2: All grants are monitored in several ways. First, there is a due diligence process in awarding the grant followed by an executed agreement with a scope of work. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Second, the Organization requires monthly, quarterly, and/or annual financial reports from recipients prior to sending the subsequent payment. Third, and as needed, the Organization performs site visits. And finally, if deemed necessary, the Organization has a third party review the program impact and/or accounting records of the recipient(s). X X X X X X X 1 Changing Our World 2000 L Street NW Suite 300 Washington DC 20036 Baseline research & campaign design 0 219247 720011 -500764 219247 720011 -500764 DC MD NY 1 Centers for Disease Control & Prevention PO Box 15580 Atlanta GA 30333 256000 Advocacy for control of Pertussis Earth Institute Columbia University 1210 Amsterdam Ave New York NY 10027 135598093 501(c)(3) 671176 Rwanda NTD Control Helen Keller International 352 Park Ave South New York NY 10010 135562162 501(c)(3) 9250 Trachoma control in Tanzania University of Notre Dame University of Notre Dame Notre Dame IN 46556 20872 NTD control in Haiti Pan America Health Organization 525 23rd Street Washington DC 20037 501(c)(3) 141009 Advocacy for Control of Various Diseases The George Washington University 44983 Knoll Square Ashburn VA 20147 530196584 501(c)(3) 2962899 Vaccine Development The World Bank 1818 H Street NW Washington DC 20433 50000 NTD control in the Democratic Republic of Congo 6 1 Procedure for Monitoring Grants in the U.S.: Part I, Line 2: Schedule I, Part I, Line 2: All grants are monitored in several ways. First, there is a significant due diligence process in awarding the grant followed by an executed agreement with a scope of work. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Second, the Organization requires monthly, quarterly, and/or annual financial reports from recipients prior to sending the subsequent payment. Third, and as needed, the Organization has site visits. Finally, if deemed necessary, the Organization has a third party review the accounting records of the recipient(s). X X X X X 0 0 0 0 0 0 0 0 0 Ciro de Quadros 298692 0 25000 0 0 0 0 0 1450 0 325142 0 0 0 Brian Davis 194967 0 25000 0 0 0 8000 0 15086 0 243053 0 0 0 Michael Marine 223057 0 10000 0 0 0 7667 0 1998 0 242722 0 0 0 Stephanie Hedean 185101 0 0 0 0 0 4056 0 6715 0 195872 0 0 0 David Diemert 170663 0 0 0 0 0 6864 0 6639 0 184166 0 0 0 Mike McQuestion 150715 0 0 0 0 0 6057 0 14856 0 171628 0 0 0 Kelly Funk 193177 0 0 0 0 0 0 0 0 0 193177 0 0 0 Kari Stoever 385000 0 0 0 0 0 0 0 0 0 385000 0 0 0 Form 990, Part VI, Section B, line 11 The Form 990 is prepared by an outside tax accountant. It is first reviewed by the Chief Operating Officer and then presented to the Finance Committee for their review and approval. Finally, it is presented to the full Board of Trustees for their review and approval before filing. Form 990, Part VI, Section B, line 12c The Organization's Ethics & Compensation Committee is responsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with the Compensation and Ethics Committee. The Organization uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation consultant and its own internal pay scale. Form 990, Part VI, Section C, line 19 The Organization's financial statements are included on its website. Also, the Organization's governing documents and conflict of interest policy are available upon request. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.